

Amendments to the Specification

Please amend the Specification as follows:

Replace the paragraph that begins at line 20 of page 5 and ends at line 7 of page 6 with the following paragraph:

The present invention relates to methods for cleaving IAP, both *in vivo* and *in vitro*, wherein an Omi family polypeptide or polynucleotide sequence is used to promote the cleavage of IAP. In particular, the present invention relates to an active Omi polypeptide that cleaves IAP and renders it non-functional. The Omi family polypeptides will include Omi wild type (WT) sequences and mutant versions, which cleave IAP. Among the available mutant Omi family polypeptides are Omi Δ PDZ, SEQ ID NOs. 48 – 51, 56, 57, 60 – 63, and 66-75 and Omi Δ AVPS, SEQ ID NOs. 52 and 53. Additionally, an Omi catalytic triad may be used to cleave IAP.

Related to the polypeptides are nucleic acid sequences, which express the polypeptides. Various methods can be used to deliver the Omi nucleic acid sequences, or polynucleotides, or the Omi polypeptides. Additionally, mutant versions can be used to block or inhibit Omi WT from cleaving IAP. In particular, an AVPS small molecule can be developed, which inhibits the binding of Omi WT, for example, to an IAP.

Replace the paragraph that begins at line 21 of page 10 and ends at line 22 of page 10 with the following paragraph:

~~Fig. 1 relates~~ Figs. 1A-1E relate to Omi cleavage of IAP proteins, different IAP proteins were incubated in the absence or presence of various amounts of Omi WT or the protease dead mutant Omi SA;

Replace the paragraph that begins at line 18 of page 11 and ends at line 19 of page 11 with the following paragraph:

~~Fig. 2 shows~~ Figs. 2A-2D show Omi/HtrA2 Cleavage of cIAP1 and the relation to the AVPS IAP binding motif;

Replace the paragraph that begins at line 1 of page 12 and ends at line 4 of page 12 with the following paragraph:

Fig. 2B shows the cleavage of cIAP1 by various Omi proteins; 50 nM of cIAP was incubated with 2.5 nM of Omi WT (lane 2), varying amounts of Omi Δ 8 mutant (lanes 3-7) or Omi Δ PDZ mutant (lanes 8-12) in a final volume of 50 μ l PBST, the asterisk (*) in ~~panel B~~ Fig. 2 indicates a cleavage product produced exclusively by Omi Δ PDZ proteolysis of cIAP1;

Replace the paragraph that begins at line 7 of page 12 and ends at line 10 of page 12 with the following paragraph:

Fig. 2D shows the cleavage of β -casein by various Omi proteins; 200 nM of β -casein which was incubated with 2.5 nM of Omi WT (lane 2), varying amounts of Omi Δ 8 mutant (lanes 3-7) or Omi Δ PDZ mutant (lanes 8-12) in a final volume of 50 μ l PBST, ~~the asterisk (*) in panel B indicates a cleavage product produced exclusively by Omi Δ PDZ proteolysis of β -casein;~~

Replace the paragraph that begins at line 11 of page 12 and ends at line 12 of page 12 with the following paragraph:

~~Fig. 3 shows~~ Figs. 3A and 3B show cIAP1 cleavage by Omi/HtrA2 and how cleavage reduces cIAP1's caspase inhibitory activity;

Replace the paragraph that begins at line 20 of page 12 and ends at line 21 of page 12 with the following paragraph:

~~Fig. 4 shows~~ Figs. 4A and 4B show that cIAP1 cleavage by Omi/HtrA2 attenuates its Ub ligase activity on caspase substrates;

Replace the paragraph that begins at line 9 of page 13 and ends at line 14 of page 13 with the following paragraph:

Figs. 4B and 4C show assay for the Ub ligase activity of cIAP1 before and after cleavage, the substrates caspase-3 (400 nM, ~~Panel Fig. 4B~~) and caspase-9 (400 nM, ~~Panel Fig. 4C~~) were incubated with varying concentrations of either full length or Omi-cleaved cIAP1 (25-150 nM) in a 20- μ l reaction volume under the same assay conditions as described in ~~panel Fig. 4A of this figure~~, the ubiquitination on caspase substrates was subsequently checked by immunoblotting, using either an antibody against caspase-3 (~~Panel Fig. 4B~~) or caspase-9 (~~Panel Fig. 4C~~);

Replace the paragraph at line 15 of page 13 with the following paragraph:

~~Fig. 5 shows~~ Figs. 5A and 5B show mapping of Omi/HtrA2 cleavage sites on cIAP1;

Replace the paragraph that begins at line 16 of page 13 and ends at line 2 of page 14 with the following paragraph:

Fig. 5A shows the results of incubating about 5 μ g of full-length cIAP1 (GST-fused) with 0.4 μ g of Omi WT, the cleaved cIAP1 sample, together with Omi (lane 2), the full-length cIAP1 alone (lane 1), and Omi alone (lane 3) were subjected to electrophoresis on a 7.5-20% linear gradient gel, four cleavage polypeptide fragments (~~panel A, F1-F4~~) were generated, 10 pmol of each fragment was excised and subjected to N-terminal sequencing by the Edman Degradation method, the two 30 kDa polypeptides in lane 2 are GST as determined by N-terminal sequencing, several degraded polypeptide bands are already in the full-length cIAP1 preparation, such as that labeled with an asterisk (*), amino acid sequencing confirmed that this band was a fragment of cIAP1 starting from Serine 147, and identical to the band appearing in the OmiWT-treated sample (labeled with an arrow plus an asterisk);

Replace the paragraph that begins at line 9 of page 14 and ends at line 10 of page 14 with the following paragraph:

~~Fig. 6 shows~~ Figs. 6A - 6D show that Omi cleaves cIAP1 in cells, and this cleavage promotes caspase activation in etoposide-induced cell death;

Replace pages 77 through 80 with the following:

All references cited in the preceding text of the patent application or in the following reference list, to the extent that they provide exemplary, procedural, or other details supplementary to those set forth herein, are specifically incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

REFERENCE LIST

Chai, J., Du, C., Wu, J. W., Kyin, S., Wang, X., and Shi, Y. (2000). Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature* *406*, 855-862.

Chai, J., Shiozaki, E., Srinivasula, S.M., Wu, Q., Datta, P., Alnemri, E.S., Shi, Y., and Dataa, P. (2001). Structural basis of caspase-7 inhibition by XIAP. *Cell* *104*, 769-780.

~~Carrol, W.L., et al., J. Immunol. Methods 89:61 (1986).~~

Carroll, W.L., Thielemans, K., Dilley, J., and Levy, R. (1986). Mouse X Human Heterohybridomas as Fusion Partners with Human B Cell Tumors. J. Immunol. Methods, 89:61-72.

Cryns, V., and Yuan, J. (1998). Proteases to die for. *Genes Dev* *12*, 1551-1570. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* *102*, 33-42.

~~Current Topics in Microbiology and Immunology 152: 183-193 (Bosma, M.J., Schuler, W. eds.)~~

Du, C., et al., Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition, Cell, Vol. 102, July 7, 2000, pages 33-42

~~Enari et al., 1998 Nature 391, 43-50.~~

Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998). A Caspase-Activated DNase that Degrades DNA During Apoptosis, and its Inhibitor ICAD. Nature, 391, 43-50.

Faccio, L., Fusco, C., Chen, A., Martinotti, S., Bonventre, J.V., and Zervos, A.S. (2000). Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem 275, 2581-2588.

Gray, C.W., Ward, R.V., Karran, E., Turconi, S., Rowles, A., Viglienghi, D., Southan, C., Barton, A., Fantom, K.G., West, A., et al. (2000). Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem 267, 5699-5710.

Green, D.R. (2000). Apoptotic pathways: paper wraps stone blunts scissors. Cell 102, 1-4.

Hegde, R., Srinivasula, S.M., Zhang, Z., Wassell, R., Mukattash, R., Cilenti, L., DuBois, G., Lazebnik, Y., Zervos, A.S., Fernandes-Alnemri, T., and Alnemri, E.S. (2002). Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 277, 432-438.

Holley, C.L., Olson, M.R., Colon-Ramos, D.A., and Kornbluth, S. (2002). Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translation inhibition. Nat Cell Biol 4, 439-444.

Hsueh, R. and Roach, T., Characterization of Cells by Flow Cytometry, Version 1.

Huang, D.C., and Strasser, A. (2000). BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103, 839-842.

Huang, H., Joazeiro, C.A., Bonfoco, E., Kamada, S., Levenson, J.D., and Hunter, T. (2000). The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 275, 26661-26664.

Huang, Y., Park, Y.C., Rich, R.L., Segal, D., Myszka, D.G., and Wu, H. (2001). Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104, 781-790.

~~Lazebnik, et al., 1995 Proc. Natl. Acad. Sci. USA 92, 9042-9046.~~

Lazebnik, Y.A., Takahashi, A., Moir, R.D., Goldman, R.D., Poirier, G.G., Kaufmann, S.H., and Earnshaw, W.C. (1995). Studies of the Lamin Proteinase Reveal Multiple Parallel Biochemical Pathways During Apoptotic Execution. Proc. Nat'l. Acad. Sci. USA, 92, 9042-9046.

Li, F., Ambrosini, G., Chu, E.Y., Plescia, J., Tognin, S., Marchisio, P.C., and Altieri, D.C. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. *Nature* 396, 580-584.

Li, W., Srinivasula, S.M., Chai, J., Li, P., Wu, J.W., Zhang, Z., Alnemri, E.S., and Shi, Y. (2002). Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. *Nat Struct Biol* 9, 436-441.

Liu, X., Kim, C.N., Yang, J., Jemmerson R., and Wang, X. (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell* 86, 147-157.

~~Liu et al., 1997 Cell 89, 175-184.~~

Liu, X., Zou, H., Slaughter, C., and Wang, X. (1997). DFF, a Heterodimeric Protein That Functions Downstream of Caspase-3 to Trigger DNA Fragmentation During Apoptosis. Cell 89, 175-184.

Locksley, R.M., Killeen, N., and Lenardo, M.J. (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. *Cell* 104, 487-501.

~~Martin et al., 1996 J. Biol. Chem. 2.~~

Martins, L.M., Iaccarino, I., Tenev, T., Gschmeissner, S., Totty, N.F., Lemoine, N.R., Savopoulos, J., Gray, C.W., Creasy, C.L., Dingwall, C., and Downward, J. (2002). The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. *J Biol Chem* 277, 439-444.

McCune, J.M., Kaneshima, H., Lieberman, M., Weissman, L.L. and Namikawa, R. (1989). The Scid-hu Mouse: Current Status and Potential Applications. Current Topics in Microbiology and Immunology, 152: 183-193.

Miller, L.K. (1999). An exegesis of IAPs: salvation and surprises from BIR motifs. *Trends Cell Biol* 9, 323-328.

Nagata, S. (1997). Apoptosis by death factor. *Cell* 88, 355-365.

Pickart, C.M. (2001). Mechanisms underlying ubiquitination. *Annu Rev Biochem* 70, 503-533.

Rathmell, J.C., and Thompson, C.B. (1999). The central effectors of cell death in the immune system. *Annu Rev Immunol* 17, 781-828.

~~Sahara et al., 1999 Nature 401, 168-173.~~

Sahara, S., Aoto, M., Eguchi, Y., Imamoto, N., Yoneda, Y., and Tsujimoto, Y. (1999). Acinus is a Caspase-3-Activated Protein Required for Apoptotic Chromatin Condensation. Nature 401, 168-173.

Salvesen, G.S., and Duckett, C.S. (2002). Apoptosis: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3, 401-410.

~~Samoszuk, M.K., et al., Hybridoma 6:605 (1987)~~

Samoszuk, M.K., Sholly, S., and Epstein, A.L. (1987). Screening for Anti-Idiotypic Monoclonal Antibodies on Paraformaldehyde-fixed Lymphoma Cells. Hybridoma, 6:605-610.

Shi, Y. (2002). A conserved tetrapeptide motif: Potentiating apoptosis through IAP-binding. Cell Death and Differentiation 9, 93-95.

Srinivasula, S.M., Hegde, R., Saleh, A., Datta, P., Shiozaki, E., Chai, J., Lee, R.A., Robbins, P.D., Fernandes-Alnemri, T., Shi, Y., and Alnemri, E.S. (2001). A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112-116.

Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., and Takahashi, R. (2001). A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8, 613-621.

Takahashi, A., Musy, P.Y., Martins, L.M., Poirier, G.G., Moyer, R.W., and Earnshaw, W.C. (1996). CrmA/SPI-2 Inhibition of an Endogenous ICE-related Protease Responsible for Lamin A Cleavage and Apoptotic Nuclear Fragmentation. The Journal of Biological Chemistry, Vol. 271, No. 51, Issue of December 20, pp. 32487-32490.

Thornberry, N.A., and Lazebnik, Y. (1998). Caspases: enemies within. Science 281, 1312-1316.

~~Thielmans, K., et al., J. Immunol. 133:495 (1984).~~

Thieleman, K., Maloney, D.G., Meeker, T., Fujimoto, J., Doss, C., Warnke, R.A., Bindl, J., Gralow, J., Miller, R.A., and Levy, R. (1984). Strategies for Production of Monoclonal Anti-Idiotypic Antibodies Against Human B Cell Lymphomas. J. Immunol. 133:495-501.

van Loo, G., van Gurp, M., Depuydt, B., Srinivasula, S.M., Rodriguez, I., Alnemri, E.S., Gevaert, K., Vandekerckhove, J., Declercq, W., and Vandenabeele, P. (2002). The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ 9, 20-26.

Vaskovsky, V.E. and Kostetsky, E.Y., Lipid Res. 9:396 (1968).

Verhagen, A.M., Coulson, E.J., and Vaux, D.L. (2001). Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. *Genome Biol* 2, REVIEWS3009.

Verhagen, A.M., Ekert, P.G., Pakusch, M., Silke, J., Connolly, L.M., Reid, G.E., Moritz, R.L., Simpson, R.J., and Vaux, D.L. (2000). Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* 102, 43-53.

Verhagen, A.M., Silke, J., Ekert, P.G., Pakusch, M., Kaufmann, H., Connolly, L.M., Day, C.L., Tikoo, A., Burke, R., Wrobel, C., et al. (2002). HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. *J Biol Chem* 277, 445-454.

Wang, X. (2001). The expanding role of mitochondria in apoptosis. *Genes Dev* 15, 2922-2933.

Wu, G., Chai, J., Suber, T.L., Wu, J.W., Du, C., Wang, X., and Shi, Y. (2000). Structural basis of IAP recognition by Smac/DIABLO. *Nature* 408, 1008-1012.

Wu, J.W., Cocina, A.E., Chai, J., Hay, B.A., and Shi, Y. (2001). Structural analysis of a functional DIAP1 fragment bound to grim and hid peptides. *Mol Cell* 8, 95-104.

Yang, Y., Fang, S., Jensen, J.P., Weissman, A.M., and Ashwell, J.D. (2000). Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. *Science* 288, 874-877.

Zor, T., and Selinger, Z. (1996). Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. *Anal. Biochem.* 236, 302-308.